-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $80

Benzinga·05/14/2026 17:00:48
Listen to the news
Morgan Stanley analyst Sean Laaman maintains Disc Medicine (NASDAQ:IRON) with a Overweight and raises the price target from $75 to $80.